Abstract
Purpose
Intravitreal somatostatin (SST) levels are decreased in patients with diabetic macular oedema. This deficit may be involved in the pathogenesis of this condition. The aim of the present study was to determine SST concentration in the vitreous fluid of patients with chronic uveitic macular oedema (CUMO) and quiescent intraocular inflammation.
Methods
Plasma and vitreous fluid samples were obtained during vitrectomy from 11 eyes of patients with CUMO and from 42 eyes of control subjects (idiopathic epiretinal membrane, macular hole). SST concentration was measured by radioimmunoassay. Statistics: χ2-square test, Mann–Whitney U-test, Wilcoxon test, Spearman’s rank correlation coefficient, and multivariant linear regression models.
Results
Plasma SST concentrations were similar in uveitic patients and controls (28.25 pg/ml (21.3–31) vs 28.7 pg/ml (22–29.5); P=0.869). A higher vitreous concentration of proteins was found in uveitic patients (1.59±0.38 mg/ml vs 0.73±0.32 mg/ml, P<0.0001). Vitreous SST was markedly lower in uveitic patients, both in absolute terms and after adjusting for total intravitreous protein concentration (39.37 pg/ml (6.16–172) vs 486.73 pg/ml (4.7–1833), P<0.0001; 33.1 pg/mg (3.9–215.74) vs 629.75 pg/mg (6.91–2024), P<0.0001). No correlations were found between plasma and vitreous concentration of SST in either group (ρ=0.191, P=0.57 and ρ=0.49, P=0.66). There were no correlations between vitreous SST concentration and visual acuity or macular thickness in uveitic patients (ρ=0.302, P=0.31 and ρ=0.45, P=0.13).
Conclusions
Intravitreous SST is decreased in patients with CUMO and quiescent intraocular inflammation. The deficit of SST may have a role in the pathogenesis of this condition.
Similar content being viewed by others
Introduction
Macular oedema is a major cause of visual loss in patients with uveitis.1 This condition occurs in two very different clinical scenarios: one in which intraocular tissues are actively inflamed, as in acute vitritis, retinitis, vasculitis, or anterior uveitis, and the other in which the inflammation is quiescent, but macular oedema persists as a chronic condition. The pathogenesis of uveitic macular oedema is not completely understood. The release and diffusion of cytokines may have a predominant role in the first scenario, but the exact factors and events responsible for the development of chronic macular oedema without active inflammation have not yet been identified.2
Somatostatin (SST) is a ubiquitous hormone that was initially identified as an inhibitory factor on the growth hormone axis.3 SST and its receptors are expressed in the uvea, retinal pigment epithelium (RPE) and neuroretina, and the receptors are expressed in the vascular endothelium.4, 5, 6 A role for SST in the maintenance of blood-retinal barrier integrity has been suggested based on its positive effect on apical-to-basal fluid transport across RPE cells.4 In a previous study, we found lower vitreous levels and lower intraocular production of SST in patients with diabetic macular oedema, suggesting that SST deficit may contribute to oedema formation.7 In addition, we showed that retinal neurodegeneration, which occurs before vascular alterations develop, could be responsible for the decreased SST production in diabetic patients.5 The aim of the present study was to determine the vitreous levels of SST in patients with chronic uveitic macular oedema (CUMO) and quiescent intraocular inflammation to evaluate whether there is a relationship between SST deficit and the development of this complication. As SST-28 is the main molecular variant in the vitreous fluid8 it was selected as the best candidate to examine for this purpose.
The study and data accumulation were carried out with the approval of the ethics committee of hospital Vall d’Hebron and in accordance with the ethical standards laid down in the 1964 Declaration of Helsinky. Informed consent for the research was obtained from the patients before their inclusion in the study.
Material and methods
Patients
The study included 11 eyes from 11 patients with CUMO and 42 eyes from 42 control subjects in whom vitrectomy was performed. As vitrectomy is reported to be effective in the management of uveitic macular oedema,9 we apply this therapeutic option in refractory cases. Vitrectomy in the controls was performed to treat idiopathic epiretinal membrane (19 patients) or idiopathic macular hole (23 patients). Macular oedema was diagnosed by optical coherence tomography (Stratus OCT 4.0, Zeiss-Humphrey Ophthalmic Systems, Dublin, CA, USA). Only patients with inactive intraocular inflammation for the previous 3 months were included. Anterior uveitis was considered inactive based on the criteria recommended by the SUN (Standardization of Uveitis Nomenclature) study group: Grade 0 cells in the anterior chamber.10 Vitritis grade was assessed using Nussenblatt’s standard photographs.11 Only cases with grade +1 or less were included. Patients with vasculitic changes considered to be active, such as perivascular sheathing with leakage on fluorescein angiography, retinal infiltrates, papillitis, or choroiditis, were not included. Patients who had previously undergone retinal photocoagulation, intravitreous treatments in the last 6 months, or intraocular surgery in the last 3 months were excluded, as were diabetic patients.
The clinical data of patients with uveitis, including demographics, type of uveitis according to the International Uveitis Study Group classification,12 specific uveitic disease, systemic treatment at the time of vitreous tap, most recent visual acuity (VA, logMAR), macular thickness, and the duration of uveitis are shown in Table 1.
Vitreous and blood samples
Standard 20-G three-port pars plana vitrectomy was performed in all patients. Undiluted vitreous samples (∼1 ml) were obtained at the beginning of vitrectomy by aspiration into a 2 ml syringe attached to the vitreous cutter (Accurus 800 CS, Alcon, Irvine, CA, USA) with air infusion. Vitreous samples were transferred to sterile Eppendorf tubes, placed immediately on ice, and centrifuged at 12 000 g for 4 min; supernatants were stored at −80 °C. For the plasma determinations, blood samples were collected at the same time as vitrectomy. Blood was collected in BD Vacutainer tubes (Becton Dickinson, Madrid, Spain) containing aprotinin to prevent proteolysis and K3E as anticoagulant. Samples were centrifuged at 3000 g for 10 min at 4 °C and the separated plasma was stored at −80 °C until analysis.
SST-28 assessment
SST-28 was measured by a competitive radioimmunoassay (RIA) (Phoenix Pharmaceuticals Inc., Burlingame, CA, USA) after an extraction-concentration procedure with octadecylsilyl silica columns. Briefly, samples were acidified with 1% trifluoroacetic acid (TFA, HPLC grade) in water and centrifuged. Columns were activated first with a solution of 60% acetonitrile in 1% TFA, and then with 1% TFA. After loading the samples, columns were slowly washed with 1% TFA and the peptide was eluted with 60% acetonitrile in 1% TFA. Eluates were lyophilized and reconstituted with RIA buffer. The SST-28 antiserum showed 100% cross-reaction with SST-28. The detection limit of the assay was 3.49 pg/tube at 20% binding and the 50% binding intercept was 9.39 pg/tube.
Protein assessment
The concentration of vitreous proteins was determined by a turbidimetric method (Cobas 6000, Roche Diagnostics, Basel, Switzerland) based on the benzethonium chloride reaction. The detection limit of the assay was 0.04 mg/ml.
Statistical analysis
Data are expressed as the mean and SD or as the median and range. Categorical variables were compared with the χ2-square test and continuous variables with the Mann–Whitney U-test or Wilcoxon test, when appropriate. Correlations were examined with Spearman’s rank correlation coefficient. A multivariant linear regression model was used to assess whether age had an influence on vitreous SST levels. Statistical significance was set at P<0.05. All statistical analyses were performed with SPSS, version 13.0 (SPSS Inc., Chicago, IL, USA).
Results
There were 6 women and 5 men in the CUMO group and 17 women and 25 men in the control group. Median age in uveitic patients was 56 (32–86) years and 55 (28–86) in control subjects. Age and sex distribution showed no statistical differences between the groups (P=0.801, P=0.765). There were no significant differences in SST-28 plasma levels between controls and uveitic patients (28.25 pg/ml (21.3–31) vs 28.7 pg/ml (22–29.5), P=0.869). Concentration of vitreous proteins was higher in patients with CUMO than in control subjects (1.59±0.38 mg/ml vs 0.73±0.32 mg/ml, P<0.0001). Vitreous SST-28 levels were strikingly lower in patients with CUMO than in controls in both absolute terms and after correcting for vitreous protein concentration (39.37 pg/ml (6.16–172) vs 486.73 pg/ml (4.7–1833), P<0.0001; 33.1 pg/mg (3.9–215.74) vs 629.75 pg/mg (6.91–2024), P<0.0001) (Figure 1). In the control subjects, SST-28 levels were 17-fold higher in vitreous fluid than in plasma (P<0.0001), whereas in uveitic patients the difference was only 1.4-fold higher (P=0.091). No correlations were found between vitreous and plasma SST-28 levels in either uveitic or control subjects (ρ=0.191, P=0.57 and ρ=0.49, P=0.66).
We investigated whether age had an influence on local production of SST. A multivariate linear regression model was performed, which showed that such relation did not exist (P=0.207). Table 2 shows clinical data and results from laboratory determinations from both the groups.
Mean VA in CUME patients was 0.84±0.39 and mean macular thickness was 512.82±110 μm. There were no statistical correlations between SST-28 vitreous levels and VA or macular thickness (ρ=0.302, P=0.31 and ρ=0.45, P=0.13). Figure 2 shows the relationship between macular thickness and SST levels.
Discussion
In this study, vitreous and plasma levels of SST-28, the main molecular variant of this hormone in the vitreous, were measured in patients with CUMO and quiescent intraocular inflammation and in control subjects. In both uveitic patients and controls, vitreous levels of SST-28 were higher than plasma levels, a finding shown in previous studies that is consistent with reports demonstrating that SST is produced intraocularly.6, 7, 8, 13 We found that vitreous SST-28 is markedly lower in patients with CUMO than in controls, a result that merits further investigation. In a previous study, we found that patients with diabetic macular oedema and no significant ischaemia on angiography had lower vitreous SST-28 levels than controls, and that this deficit may be attributable to decreased production by neuroretina and RPE cells due to degeneration.5, 6 Chronic inflammation can cause retinal degeneration. Cytokines with pivotal roles in inflammatory processes such as tumour necrosis factor-α and interferon-γ induce apoptosis in RPE cells.14 Furthermore, interferon-γ has been shown to induce degeneration of human RPE cells through stimulation of intracellular production of reactive oxygen species and activation of caspases.15 It can be argued that degeneration of neuroretina and RPE cells due to chronic inflammation might be the cause of deficient intraocular expression of SST-28.
SST may be involved in regulating the permeability of endothelial and epithelial barriers. SST inhibits nitric oxide production,16, 17 which was found to be involved in disruption of tight junctions in Chinese hamster ovary endothelial cells.18 The human receptor of SST 3, a subtype of SST receptor, physically interacts with an epithelial tight junction protein known as MUPP1 (multiple PDZ domain protein-1), which enables SST to regulate transepithelial permeability.19 Moreover, SST inhibits insulin-like growth factor I-mediated expression of vascular endothelial growth factor (VEGF) in human RPE cells.20 Thus, if SST participates in blood-retinal barrier homoeostasis, a deficit of this hormone might be involved in the pathogenic events leading to macular oedema in uveitic patients.
Experimental studies have shown that SST has immunosuppressive properties within the eye. Taylor et al21 found that SST from rabbit aqueous humour suppressed IFN-γ production by effector T cells and mediated the induction of regulatory T cells. Hence, low levels of SST in uveitic patients may contribute to chronic inflammation, which could promote macular oedema. This could have happened in our study: although we included patients with quiescent intraocular inflammation, low-grade inflammatory activity promoting macular oedema may be present as determination of vitreous proteins showed higher levels in uveitis patients, which may be presumably due to inflammation related vascular leakage.
Interestingly, the SST analogue octreotide has shown efficacy in the treatment of CUMO in some case series and in postsurgical cystoid macular oedema in a clinical trial. Missoten et al4 studied the effect of 20 mg octreotide LAR (Novartis Pharmaceuticals, Basel, Switzerland) monthly intramuscular injections in a group of 20 uveitis patients with persistent macular oedema in an otherwise quiescent eye. Reduction of macular oedema was achieved in14 of 20 episodes. The effect of octreotide LAR was obtained after 3 or 4 injections. Papadaki et al22 reported partial resolution of macular oedema and improved VA in a patient with intermediate uveitis treated with subcutaneous octreotide injections. Shah et al23 reported an increase in VA in a group of patients with postsurgical cystoid macular oedema treated with intramuscular octreotide compared with a placebo group. However, there were no differences between the two groups regarding retinal thickening or angiographic leakage.
SST may also have a role in retinal physiology. Kouvidi et al24 reported that SST causes an increase in dopamine release in rat retinal explants. As retinal levels of dopamine are known to positively correlate with light sensitivity, SST control of dopamine release may be important for regulation of light adaptation. Dal Monte et al25 showed that activation of an SST receptor subtype, SST receptor 2, inhibits K+-induced glutamate release in mouse retinal explants. As glutamate is the major excitatory neurotransmitter in the mammalian retina and is implicated in neurotransmission along the vertical pathway from photoreceptors to bipolar cells to ganglion cells, SST may be involved in regulating this part of the visual pathway. All these data suggest that low SST production in patients with CUMO may have an impact on their visual function.
Regarding the use of vitrectomy for the treatment of CUME, it should be kept in mind that this might imply complete removal of an already deficient factor that can act against oedema. Hence, the indication for vitrectomy might be restricted to cases that are more active, in which proinflammatory cytokines are likely to have a predominant role in the blood-retinal barrier alteration.
The sample of uveitic patients in this study was small and this may have contributed to the lack of statistical correlations between vitreous SST-28 concentrations and macular thickness or VA. However, other factors may account for these results. Other peptides, such as VEGF, which is also involved in the pathogenesis of uveitic macular oedema,26 may have a greater influence on vascular permeability. Structural complications, such as corneal opacities or lens/intraocular lens opacities are also determinants for VA.
A possible relation between age and vitreous levels of SST was explored as production of the hormone may be lower due to an expected age-related decline in the number or retinal cells. However, we did not find such relation.
Perhaps this relation could be found in a study with a larger sample of patients.
Another limitation of the study was the heterogeneity of the sample in terms of aetiology. Posterior uveitis and panuveitis may be more likely to affect the source of SST, that is, RPE cells and neuroretina.
Finally, another limitation of our work is the cross-sectional nature of the study. Reliable deductions about the levels of SST as a cause of oedema and inflammation or as a possible effect of them cannot be stablished in this type of studies.
In conclusion, intravitreal SST-28 levels are decreased in patients with CUMO and quiescent intraocular inflammation. Further studies are needed to clarify the cause of this deficit and its potential contribution to the pathogenesis of CUMO.
References
Lardenoye CW, van Kooij B, Rothova A . Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006; 113: 1446–1449.
Rothova A . Inflammatory cystoid macular edema. Curr Opin Ophthalmol 2007; 18: 487–492.
Brazeau P, Vale W, Burgus R, Lingn N, Butcher M, Rivier J et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–79.
Missotten T, van Laar JAM, van der Loos TL, van Daele PL, Kuijpers RW, Baarsma GS et al. Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. Am J Ophthalmol 2007; 144: 838–843.
Carrasco E, Hernandez C, Miralles A, Huguet P, Farres J, Simo R . Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal degeneration. Diabetes Care 2007; 30: 2902–2908.
Klisovic DD, O’Dorisio MS, Katz SE, Sall JW, Balster D, O’Dorisio TM et al. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest Ophthalmol Vis Sci 2001; 42: 2193–2201.
Simo R, Carrasco E, Fonollosa A, Garcia-Arumi J, Casamitjana R, Hernandez C . Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema. Diabetes Care 2007; 30: 725–727.
Hernandez C, Carrasco E, Casamitjana R, Deulofeu R, Garcia-Arumi J, Simo R . Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care 2005; 28: 1941–1947.
Becker M, Davis J . Vitrectomy in the treatment of uveitis. Am J Ophthalmol 2005; 140: 1096–1105.
The SUN working group. Standarization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005; 140: 509–516.
Nussenblatt RB, Palestine AG, Chan CC, Roberge F . Standarization for vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467–471.
Bloch-Michel E, Nussenblatt RB . International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987; 103: 234–235.
van Hagen PM, Baarsma GS, Mooy CM, Ercoskan EM, ter Averst E, Hofland LJ et al. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 2000; 143 (Suppl 1): S43–S51.
Li R, Maminishkis A, Wang FE, Miller SS . PDGF-C and -D induced proliferation/migration of human RPE is abolished by inflammatory cytokines. Invest Ophthalmol Vis Sci 2007; 48: 5722–5732.
Elner SG, Yoshida A, Bian ZM, Kindezelskii AL, Petty HR, Elner VM . Human RPE cells apoptosis induced by activated monocytes is mediated by caspase-3 activation. Trans Am Ophthalmol Soc 2003; 101: 77–89.
Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha Vaz J, Ambrosio AF et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2007; 48: 5257–5265.
Olson N, Greul AK, Hristova M, Bove PF, Kasahara DI, van der Vliet A . Nitric oxide and air way epithelial barrier function: regulation of tight junctions proteins and epithelial permeability. Arch Biochem Biophys 2009; 484: 205–213.
Arena S, Pattarozzi A, Corsaro A, Schettini G, Florio T . Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways. Mol Endocrinol 2005; 19: 255–267.
Liew CW, Vockel M, Glassmeier G, Brandner JM, Fernandez-Ballester GJ, Schwartz JR et al. Interaction of the human somatostatin receptor 3 with the multiple PDZ domain protein MUPP1 enables somatostatin to control permeability of epithelial tight junctions. FEBS Lett 2009; 583: 49–54.
Sall JW, Klisovic DD, O’Dorisio MS, Katz SE . Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. Exp Eye Res 2004; 79: 465–476.
Taylor AW, Yee DG . Somatostatin is an immunosuppressive factor within aqueous humor. Invest Ophthalmol Vis Sci 2003; 44: 2644–2649.
Papadaki T, Zacharopoulos I, Iaccheri B, Fiore T, Foster CS . Somatostatin for Uveitic Cystoid Macular Edema (CME). Ocul Immunol Inflamm 2005; 13: 469–470.
Shah SM, Nguyen QD, Mir HS, Polito A, Hafiz G, Tatlipinar S et al. A randomized, double-masked controlled clinical trial of Sandostatin long-acting release depot in patients with postsurgical cystoid macular edema. Retina 2010; 30: 160–166.
Kouvidi E, Papadopoulou-Daifoti Z, Thermos K . Somatostatin modulates dopamine release in rat retina. Neurosci Lett 2006; 391: 82–86.
Dal Monte M, Petrucci C, Cozzi A, Allen JP, Bagnoli P . Somatostatin inhibits potassium-evoked glutamate release by activation of the sst(2) somatostatin receptor in the mouse retina. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 188–192.
Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB . Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001; 132: 794–796.
Acknowledgements
This study was financially supported by: Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Madrid, Spain, grant numbers FIS PI/070414 and RETICS RD07/0062, and Gobierno vasco, grant number IT-437-10. We gratefully acknowledge Lorea Martinez-Indart for her assistance in the statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
The present study was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Fort Lauderdale, Florida, May 2–6 2010.
Rights and permissions
About this article
Cite this article
Fonollosa, A., Coronado, E., Catalan, R. et al. Vitreous levels of somatostatin in patients with chronic uveitic macular oedema. Eye 26, 1378–1383 (2012). https://doi.org/10.1038/eye.2012.161
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2012.161